Literature DB >> 7744401

Incidence of symptomatic urinary tract infections in HIV seropositive patients and the use of cotrimoxazole as prophylaxis against Pneumocystis carinii pneumonia.

J K Evans1, A McOwan, R J Hillman, G E Forster.   

Abstract

OBJECTIVES: To determine the incidence of symptomatic urinary tract infections in HIV seropositive patients and to assess whether this varies with stage of disease, risk group or the use of co-trimoxazole as prophylaxis against Pneumocystis carinii pneumonia.
METHODS: A retrospective case note review of 175 HIV-infected patients attending The Royal London Hospital between July 1988 and December 1992 was performed. A urinary tract infection was defined as a pure culture of > or = 10(5) colony forming units in a mid-stream specimen of urine from a patient with symptoms consistent with a urinary tract infection.
RESULTS: Urinary tract infections occurred in 10 (5.7%) of 175 patients, with an incidence of 1.49 per hundred patient years. Urinary tract infections were significantly more common in patients with AIDS or a CD4 lymphocyte count below 0.2 x 10(9)/l (or both) when compared to those without AIDS and a CD4 lymphocyte count above 0.2 x 10(9)/l (5.4 vs. 0.5 urinary tract infections per hundred patient years, p = 0.00005). Women with AIDS or a CD4 count below 0.2 x 10(9)/l (or both) had an incidence of urinary tract infection of 18.5 per hundred patient years. No significant difference was found between the incidence of urinary tract infections in those taking co-trimoxazole as Pneumocystis carinii pneumonia prophylaxis and those taking alternative or no prophylaxis (2.6 vs 6.4 per hundred patient years, p = 0.39).
CONCLUSIONS: Urinary tract infection represents a considerable health problem amongst HIV infected patients. Our data show that urinary tract infections are more common in patients with advanced compared with early HIV infection. Cotrimoxazole, when taken by patients as prophylaxis against Pneumocystis carinii pneumonia did not appear to reduce the incidence of urinary tract infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744401      PMCID: PMC1195467          DOI: 10.1136/sti.71.2.120

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  10 in total

Review 1.  Diagnosis and management of urinary tract infection in adults.

Authors:  M E Wilkie; M K Almond; F P Marsh
Journal:  BMJ       Date:  1992-11-07

2.  Bacteriuria in patients with CDC group IV manifestations: a prospective study.

Authors:  A M Pinho; D V Maranconi; B M Moreira; K M Rodrigues; N A Paz; C F Ramos-Filho; M Schechter
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

Review 3.  Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment.

Authors:  B A Lipsky
Journal:  Ann Intern Med       Date:  1989-01-15       Impact factor: 25.391

Review 4.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

5.  Prevalence of urinary tract infection in homosexual and heterosexual men.

Authors:  A P Wilson; S J Tovey; M W Adler; R N Grüneberg
Journal:  Genitourin Med       Date:  1986-06

6.  Urinary-tract infection in sexually active homosexual men.

Authors:  R C Barnes; R Daifuku; R E Roddy; W E Stamm
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

7.  Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.

Authors:  A Carr; B Tindall; B J Brew; D J Marriott; J L Harkness; R Penny; D A Cooper
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

8.  Value of bacteriological screening of urine samples from HIV infected patients.

Authors:  M Bain; F X Emmanuel; L Willocks; F Cowan; R P Brettle
Journal:  Int J STD AIDS       Date:  1992 Sep-Oct       Impact factor: 1.359

9.  Bacteriuria in men infected with HIV-1 is related to their immune status (CD4+ cell count).

Authors:  A I Hoepelman; M van Buren; J van den Broek; J C Borleffs
Journal:  AIDS       Date:  1992-02       Impact factor: 4.177

10.  A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.

Authors:  W D Hardy; J Feinberg; D M Finkelstein; M E Power; W He; C Kaczka; P T Frame; M Holmes; H Waskin; R J Fass
Journal:  N Engl J Med       Date:  1992-12-24       Impact factor: 91.245

  10 in total
  5 in total

1.  One size doesn't fit all: unraveling the diversity of factors and interactions that drive E. coli urovirulence.

Authors:  Henry L Schreiber; Caitlin N Spaulding; Karen W Dodson; Jonathan Livny; Scott J Hultgren
Journal:  Ann Transl Med       Date:  2017-01

2.  Urine Cytokine and Chemokine Levels Predict Urinary Tract Infection Severity Independent of Uropathogen, Urine Bacterial Burden, Host Genetics, and Host Age.

Authors:  Chelsie E Armbruster; Sara N Smith; Lona Mody; Harry L T Mobley
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

3.  Isolation and Antibiotic Susceptibility Pattern of Bacterial Uropathogens and Associated Factors Among Adult People Living with HIV/AIDS Attending the HIV Center at Wolaita Sodo University Teaching Referral Hospital, South Ethiopia.

Authors:  Admasu Haile Hantalo; Kassahun Haile Taassaw; Fithamlak Solomon Bisetegen; Yimtubezenash Woldeamanuel Mulate
Journal:  HIV AIDS (Auckl)       Date:  2020-11-27

4.  Prevalence and risk factors of asymptomatic bacteriuria among children living with HIV in Lagos, Nigeria.

Authors:  Adeseye Michael Akinsete; Chinyere Ezeaka
Journal:  Pan Afr Med J       Date:  2018-11-14

5.  Effectiveness of Preanalytic Practices on Contamination and Diagnostic Accuracy of Urine Cultures: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis.

Authors:  Mark T LaRocco; Jacob Franek; Elizabeth K Leibach; Alice S Weissfeld; Colleen S Kraft; Robert L Sautter; Vickie Baselski; Debra Rodahl; Edward J Peterson; Nancy E Cornish
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.